Managing respiratory failure in preterm infants often requires supplemental oxygen. While life-saving, this therapy frequently leads to hyperoxia-induced pulmonary vascular injury. Recent evidence published in June 2026 highlights the critical role of vascular damage in the pathogenesis of Bronchopulmonary Dysplasia (BPD).

Mechanisms of Hyperoxia-induced Pulmonary Vascular Injury

A systematic review of 55 studies reveals that the injury process is remarkably complex. Instead of a single cause, a multifaceted network drives the damage. Specifically, signaling pathways, epigenetic modifications, and metabolic dysregulation interact to disrupt normal development. Furthermore, these factors cause phenotypic alterations in the pulmonary vasculature. These changes ultimately support the vascular hypothesis, which suggests that impaired vessel growth leads to arrested alveolar development.

Moreover, the study indicates that epigenetic changes play a significant role in how infants respond to oxygen. Additionally, metabolic dysregulation exacerbates the oxidative stress already present in underdeveloped lungs. Consequently, clinicians must recognize BPD as a multi-organ, multi-systemic challenge rather than just a localized lung issue.

Emerging Therapies and Clinical Gaps

Researchers are currently investigating diverse therapeutic strategies. These include targeting specific signaling molecules and using antioxidant interventions. However, the vast majority of these treatments remain in the preclinical phase. Therefore, the most significant gap in the field today is the lack of clinical translation. Moving these promising laboratory findings into neonatal intensive care units is the next vital step for research.

Frequently Asked Questions

What is the vascular hypothesis in BPD?

The vascular hypothesis proposes that healthy pulmonary vascular development is essential for alveolar growth. Therefore, any injury to the vessels, such as that caused by hyperoxia, directly prevents the lungs from maturing properly.

Why is clinical translation difficult for BPD therapies?

Clinical translation is challenging because most studies are currently preclinical. Additionally, the multifactorial nature of BPD makes it difficult to design human trials that isolate specific therapeutic effects in vulnerable preterm populations.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

Cai J et al. Hyperoxia and pulmonary vascular injury in bronchopulmonary dysplasia: pathogenic mechanisms and emerging therapies-a systematic review. Pediatr Res. 2026 Jun 08. doi: 10.1038/s41390-026-05150-w. PMID: 42260307.

Jobe AH. Mechanisms of Lung Injury and Bronchopulmonary Dysplasia. Am J Perinatol. 2016 Nov;33(11):1076-1078. doi: 10.1055/s-0036-1586106.

Cosgrove E et al. Recent Advances in the Management of Bronchopulmonary Dysplasia. Curr Treat Options Peds. 2025 Jul. doi: 10.1007/s40746-025-00334-8.